Breaking News Instant updates and real-time market news.

MDWD

MediWound

$5.50

0.355 (6.90%)

, TEVA

Teva

$16.35

-0.73 (-4.27%)

07:09
03/25/19
03/25
07:09
03/25/19
07:09

MediWound reports Q4 EPS 39c, consensus (15c)

The company's net profit in 2018 included one-time other income of $12.1M as a result of the settlement with Teva, which was partially recorded as discontinued operation. Reports Q4 revenue $992K, consensus $810K. Throughout 2019, the company will continue to invest primarily in research and development efforts for EscharEx, while NexoBrid research and development programs will be funded by BARDA. As a result, the company expects cash use for operating activities in 2019 to be in the range of $12M-$14M.

MDWD

MediWound

$5.50

0.355 (6.90%)

TEVA

Teva

$16.35

-0.73 (-4.27%)

  • 25

    Mar

  • 25

    Mar

MDWD MediWound
$5.50

0.355 (6.90%)

08/08/18
WELS
08/08/18
NO CHANGE
Target $11
WELS
Outperform
MediWound could be sold for 'substantially higher price,' says Wells Fargo
Wells Fargo analyst David Maris noted that MediWound's Chairman said on the company's earnings call that while the board previously thought it would have more clarity by its Q2 report on its previously disclosed consideration of a potential strategic transaction, the company is taking a "comprehensive and measured approach" as it is still in talks with several parties. If MediWound is able to conclude a strategic combination, it would be for "a substantially higher price" and one that contemplates cash flows beyond Maris' current assumptions, he stated. Maris keeps an Outperform rating and $11 price target on MediWound shares.
09/25/18
WELS
09/25/18
NO CHANGE
Target $11
WELS
Outperform
MediWound BARDA contract 'highly value-creating,' says Wells Fargo
Wells Fargo analyst David Maris estimates MediWound's new BARDA contract to develop NexoBrid for the treatment of Sulfur Mustard injuries should be worth approximately $1 per share. The analyst views the deal as an "endorsement of the promise" of NexoBrid and the potential for longer-term government contracts if approved. He currently does not model NexoBrid government sales but believes the size of the mass casualty preparedness market could rival the burn market. Overall, the contract from the U.S. Biomedical Advanced Research and Development Authority is a "highly value-creating deal," Maris tells investors in a research note. He keeps an Outperform rating on MediWound with an $11 price target.
03/12/19
RHCO
03/12/19
NO CHANGE
Target $9
RHCO
Buy
MediWound may be near strategic deal, says SunTrust
After MediWound announced that CEO Gal Cohen has decided to step down, SunTrust analyst Bruce Nudell said he believes the fact that Cohen is pursuing another opportunity while retaining his share interest in MediWound, along with the lack of formal search for a successor, is "consistent with the notion that a strategic deal is near in hand." Nudell has a Buy rating and $9 price target on MediWound shares.
03/12/19
WELS
03/12/19
NO CHANGE
Target $11
WELS
Outperform
MediWound CEO change 'occurred from a position of strength,' says Wells Fargo
After speaking to management, Wells Fargo analyst David Maris believes the CEO change at MediWound "appears to have occurred from a position of strength" after the recently announced positive Phase III data for NexoBrid and advancing strategic discussions. The analyst continues to think the company will be able to "unlock sizable value" with a strategic transaction or partnership. Further, Maris expects MediWound "will not miss a step" transitioning to new CEO Sharon Malka. He maintains an Outperform rating on the shares with an $11 price target.
TEVA Teva
$16.35

-0.73 (-4.27%)

03/07/19
UBSW
03/07/19
INITIATION
Target $22
UBSW
Buy
Teva reinstated with a Buy at UBS
UBS analyst Navin Jacob reinstated coverage of Teva Pharmaceutical with a Buy rating and $22 price target. The U.S. generic industry is on a path to recovery, Jacob tells investors in a research note, citing his firm's generic price erosion tracker data. The analyst sees 30% potential upside and views Teva's 2019 guidance as a "hiccup."
03/07/19
03/07/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Five Below (FIVE) initiated with an Outperform at Oppenheimer. 2. Teva (TEVA) reinstated with a Buy at UBS. 3. Chiasma (CHMA) initiated with an Overweight at Cantor Fitzgerald. 4. Monster Beverage (MNST) and Constellation Brands (STZ) were initiated with an Outperform at Credit Suisse, while Procter & Gamble (PG), Coca-Cola (KO), and Church & Dwight (CHD) were initiated with a Neutral, and PepsiCo (PEP), Colgate-Palmolive (CL), and Clorox (CLX) initiated with an Underperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/13/19
WELS
03/13/19
NO CHANGE
Target $68
WELS
Market Perform
Wells says generic risk, not Purdue news, bringing down Emergent shares
Wells Fargo analyst David Maris "completely" disagrees with the view that shares of Emergent BioSolutions (EBS) are weak today on news of Purdue Pharma's nalmefene injection receiving fast track designation from the FDA. Maris notes that none of his clients have raised this as a potential issue and that, as an injection, Purdue's pproduct is not comparable to Emergent's nasal naloxone. An injection is not practical for the emergency medical technician and at home market, where most of Narcan is used, Maris tells investors in a research note. For example, Amphastar (AMPH) is a leader in the injectable market, and the vast majority of its use is in the hospital setting, the analyst points out. Rather, Maris attributes the recent selloff in Emergent BioSolutions to worries about the potential introduction of a generic version of Narcan. Teva (TEVA) has had a tentative approval for generic Narcan for some time, and its 30 month stay is over today, meaning that Teva could launch at risk from this point forward, Maris writes. As of now, there is no clear indication whether Teva will launch or not, he adds. While the analyst is not expecting an at-risk Narcan launch, he believes the risk of such an event is largely reflected in the shares given today's decline. Nonetheless, Maris keeps a Market Perform rating on Emergent with a $68 price target. The stock in afternoon trading is down 9%, or $4.98, to $52.00.
03/19/19
RHCO
03/19/19
INITIATION
Target $17
RHCO
Hold
Teva initiated with a Hold at SunTrust
SunTrust analyst Gregg Gilbert initiated Teva with a Hold rating and a price target of $17, saying that while the new CEO Kare Schultz led a cost base restructuring effort and trying to turn around the U.S. generics business, those positive are likely factored into the stock price. The analyst adds that the company's recent delay in expecting to achieve its deleveraging target "may make existing holders anxious and potential holders more patient."

TODAY'S FREE FLY STORIES

COF

Capital One

$101.39

1.8 (1.81%)

08:43
12/07/19
12/07
08:43
12/07/19
08:43
Periodicals
Capital One shares could have more upside ahead, Barron's says »

Shares of Capital One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.68

0.06 (0.13%)

08:04
12/07/19
12/07
08:04
12/07/19
08:04
Hot Stocks
AstraZeneca says Calquence combination improved survival in leukemia patients »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:01
12/07/19
12/07
08:01
12/07/19
08:01
Hot Stocks
AbbVie announces follow-up data from chronic lymphocytic leukemia study »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

07:56
12/07/19
12/07
07:56
12/07/19
07:56
Hot Stocks
AbbVie announces data from Phase 2 lymphocytic leukemia study »

AbbVie announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:51
12/07/19
12/07
07:51
12/07/19
07:51
Hot Stocks
Janssen announces initial results from Phase 1b/2 multiple myeloma study »

Janssen Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

XBIT

XBiotech

$11.11

0.1 (0.91%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:46
12/07/19
12/07
07:46
12/07/19
07:46
Hot Stocks
XBiotech sells bermekimab to Janssen for $750M plus potential milestones »

XBiotech (XBIT) announced…

XBIT

XBiotech

$11.11

0.1 (0.91%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

PCG

PG&E

$9.65

-0.13 (-1.33%)

07:39
12/07/19
12/07
07:39
12/07/19
07:39
Hot Stocks
PG&E to amend and finalize bankruptcy plan following settlement »

PG&E said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

PCG

PG&E

$9.65

-0.13 (-1.33%)

07:39
12/07/19
12/07
07:39
12/07/19
07:39
Hot Stocks
PG&E to amend and finalize bankruptcy plan following settlement »

PG&E said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

PCG

PG&E

$9.65

-0.13 (-1.33%)

07:37
12/07/19
12/07
07:37
12/07/19
07:37
Hot Stocks
PG&E announces $13.5B settlement with victims of California wildfires »

PG&E Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

07:34
12/07/19
12/07
07:34
12/07/19
07:34
Hot Stocks
Amazon leases 335,000 square feet of office space in New York City »

Amazon.com signed a lease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$335.85

5.6 (1.70%)

07:31
12/07/19
12/07
07:31
12/07/19
07:31
Hot Stocks
Tesla CEO Musk cleared in defamation suit over tweet »

A Los Angeles jury on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

ATRC

AtriCure

$30.99

1.29 (4.34%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
AtriCure management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAD

Acadia

$51.37

0.915 (1.81%)

, AMGN

Amgen

$233.74

0.3 (0.13%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
Clinical Trials on Alzheimer's Disease to hold conference »

12th Clinical Trials on…

ACAD

Acadia

$51.37

0.915 (1.81%)

AMGN

Amgen

$233.74

0.3 (0.13%)

AZN

AstraZeneca

$47.68

0.06 (0.13%)

BIIB

Biogen

$300.27

0.98 (0.33%)

CLB

Core Laboratories

$46.19

1.94 (4.38%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

MRK

Merck

$88.84

0.09 (0.10%)

NVS

Novartis

$92.08

0.42 (0.46%)

RHHBY

Roche

$0.00

(0.00%)

TAK

Takeda Pharmaceutical

$20.27

-0.16 (-0.78%)

VCNX

Vaccinex

$4.95

-0.05 (-1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 16

    Dec

  • 17

    Dec

  • 21

    Jan

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 05

    Feb

  • 14

    Mar

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

FITB

Fifth Third

$30.24

0.365 (1.22%)

, CSCO

Cisco

$43.83

0.29 (0.67%)

18:37
12/06/19
12/06
18:37
12/06/19
18:37
Hot Stocks
Fifth Third issues statement on temporary network outage »

Fifth Third Bank (FITB)…

FITB

Fifth Third

$30.24

0.365 (1.22%)

CSCO

Cisco

$43.83

0.29 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 08

    Jan

  • 12

    Feb

STML

Stemline

$10.33

0.5 (5.09%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

18:33
12/06/19
12/06
18:33
12/06/19
18:33
Hot Stocks
Stemline names Robert Francomano as Chief Commercial Officer »

Most recently, Francomano…

STML

Stemline

$10.33

0.5 (5.09%)

PFE

Pfizer

$38.29

0.26 (0.68%)

GSK

GlaxoSmithKline

$45.51

0.29 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

GOL

Gol Linhas

$17.39

1.07 (6.56%)

18:31
12/06/19
12/06
18:31
12/06/19
18:31
Hot Stocks
Gol Linhas announces preliminary traffic figures for November »

GOL's domestic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVB

Navidea

$0.97

0.07 (7.78%)

18:25
12/06/19
12/06
18:25
12/06/19
18:25
Syndicate
Navidea announces $1.9M private placement »

Navidea announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFC

Ellington Financial

$18.22

0.09 (0.50%)

18:23
12/06/19
12/06
18:23
12/06/19
18:23
Hot Stocks
Ellington Financial reports estimated book value per share $18.51 on November 30 »

This estimate includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.